Salsalate is the generic name of a prescription drug marketed under the
brandnames Mono-Gesic, Salflex, Disalcid, and Salsitab. Other generic and brand name formulations may be available.[2]
The mechanism through which salsalate is thought to reduce the production of these inflammatory chemical signals is through the inhibition of
IκB kinase resulting in decreased action of
NF-κB genes.[3][4][5] This mechanism is thought to be responsible for salsalate's
insulin-sensitizing and
blood sugar lowering properties.[4]
The risk of
bleeding is a common concern with use of the NSAID class of medications. However, the bleeding risk associated with salsalate is lower than that associated with
aspirin use.[4]
Research
Salsalate has been proposed for the prevention and treatment of
type 2 diabetes mellitus due to its ability to lower
insulin resistance associated with inflammation and may be useful in
prediabetes.[3] However, the use of salsalate to prevent the progression from prediabetes to type 2 diabetes mellitus has received limited study.[3]
History
This section is missing information about first known synthesis and commercialization — who decided to stick two salicylic acid molecules together?. Please expand the section to include this information. Further details may exist on the
talk page.(January 2023)
Salsalate had been suggested as possible treatment for diabetes as early as 1876.[3][7][8]
^
abcEsser N, Paquot N, Scheen AJ (March 2015). "Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease". Expert Opinion on Investigational Drugs (Review). 24 (3): 283–307.
doi:
10.1517/13543784.2015.974804.
PMID25345753.
S2CID23674166.
^Ebstein W (1876). "Zur therapie des diabetes mellitus, insbesondere uber die anwendung des salicylsauren natron bei demselben". Berliner Klinische Wochenschrift. 13: 337–340.
^Cavallito CJ, Buck JS (1943). "Synthesis of Phenolic Acid Esters. I. Depsides1". Journal of the American Chemical Society. 65 (11): 2140–2142.
doi:
10.1021/ja01251a034.
^Baker W, Ollis WD, Zealley TS (1951). "42. Eight- and higher-membered ring compounds. Part II. Di-, tri-, tetra-, and hexa-salicylides". Journal of the Chemical Society (Resumed): 201.
doi:
10.1039/JR9510000201.
^DE 211403, "Verfarhen zur Darstellung einer kristallisierten Salicylosalicylsäure aus Salicylsäure oder ihrne Salzen [Process for preparing a crystallized salicylosalicylic acid from salicylic acid or its salts]", published 1909-06-25, assigned to C.F. Boehringer & Söhne
^DE 214044, "Verfarhen zur Darstellung einer kristallisierten Salicylosalicylsäure [Process for preparing a crystallized salicylosalicylic acid]", published 1909-09-20, assigned to C.F. Boehringer & Söhne